Heranba Industries has designated Punit H. Vyas as Senior Management Personnel effective August 22, 2026. The Board of Directors approved the appointment during its meeting held on Saturday, August 22, 2026.

Vyas currently serves as the Quality Control - Head of the company. The designation aligns with compliance requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The move formalizes his role within the senior leadership structure.

Leadership Profile

Mr. Punit H. Vyas holds an M.Sc. in Applied Chemistry from The Maharaja Sayajirao University of Baroda. He possesses over 25 years of experience in Quality Assurance, Quality Control, Regulatory Compliance, and Laboratory Operations across pharmaceutical, specialty chemicals, and agrochemical industries.

Prior to joining Heranba Industries, Vyas held senior leadership positions at PI Industries Limited, Navin Fluorine International Limited, ZCL Chemicals Limited (Zandu Pharma), J.B. Chemicals & Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Sanofi-Aventis Pharmaceuticals Limited, and Wockhardt Pharmaceuticals Limited.

He is an FDA Approved Chemist recognized by Gujarat State Authorities. His expertise includes handling audits by USFDA, EDQM, TGA, and WHO, as well as implementing Quality Management Systems and NABL compliance.

The company stated that Vyas's extensive industry experience will contribute to strengthening quality systems and operational excellence.

Heranba Industries has postponed its board meeting scheduled for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company cited ongoing data validation and reconciliation processes necessitated by the implementation of a new Enterprise Resource Planning (ERP) system as the primary reason for the delay.

In a communication to stock exchanges on August 12, 2026, the company stated that management and statutory auditors identified matters requiring further verification during the review of financial closure procedures. These issues arose during the transition from the legacy ERP system to the new platform.

Key Reconciliation Areas

The company highlighted several specific areas requiring comprehensive verification to ensure the financial results present a true and fair view:

• Validation of opening balances
• Reconciliation of transactions migrated into the new ERP environment
• Inventory valuation records
• Fixed asset records
• GST reconciliations
• Inter-company and inter-branch balances

The company emphasized that additional time is required to conclude the financial closing process accurately and reliably before placing the information before the Audit Committee and the Board of Directors.

Trading Window Status

Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for the quarter ended June 30, 2026, has been closed since July 1, 2026. The company confirmed that the trading window will reopen only after the expiry of 48 hours from the declaration of the financial results.

A revised date for the board meeting to consider the Q1FY26 results will be intimated to the stock exchanges in due course. The company stated it is taking all necessary steps on a priority basis to complete the pending reconciliation and validation procedures.

What the Numbers Show

The delay in reporting highlights the operational complexity involved in migrating core financial systems. While no financial figures are disclosed, the specific mention of inventory valuation and fixed asset record reconciliations suggests that the integrity of balance sheet items is under scrutiny. This procedural pause ensures that any potential discrepancies between the legacy and new systems are resolved before finalizing the quarterly performance metrics.